477202-00-9
- Product Name：Ipilimumab
- Molecular Formula：C17H21Cl2N7
- Purity：99%
- Molecular Weight：394.302
Product Details:
CasNo： 477202-00-9
Molecular Formula： C17H21Cl2N7
Purity： 99%
Synonyms: ipilimumab; Ipilimumab (anti-CTLA-4); Ipilimubab; Research Grade Ipilimumab(DHD17201); BMS734016,MDX010,Ipilimumab,inhibit,BMS-734016,BMS 734016,Inhibitor,MDX 010,MDX-010
Description:
Ipilimumab is a CTLA-4 blocking antibody that was approved by the U.S. FDA in March 2011 for the treatment of unresectable or metastatic melanoma. Therefore, ipilimumab has an indirect effect on tumors that is mediated through blockade of CTLA-4 negative signaling and augmentation of T-cell activity. It is one of a handful of immunostimulatory drugs (e.g., aldesleukin and interferon alfa-2b) now approved for cancer therapy.
Uses:
Treatment of oncology disease and HIV infection.
Mechanism of action:
Anti-CTLA-4 monoclonal antibodies like ipilimumab inhibit CD80 and CD86 on APCs forms binding to CTLA-4 on T cells. The resulting blockade of CTLA-4 signaling prolongs T-cell activation, restores T-cell proliferation, and thus amplifies T-cell-mediated immunity, which theoretically enhances the patient's capacity to mount an antitumor immune response. Cancer patients with reduced CTLA-4 expression have shown a more pronounced response to blockade of the CTLA-4 pathway and less likelihood of subsequent relapse[1].
Relevant Products
-
MilvexianCAS：1802425-99-5
-
PaclitaxelCAS：33069-62-4
-
(20S)-Ginsenoside Rg3CAS：14197-60-5
